Evidence map›Paper›PMID 23849431›Full record

Trial reportEuropean neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology2013

Pharmacogenetic randomized trial for cocaine abuse: disulfiram and α1A-adrenoceptor gene variation.

D Shorter, D A Nielsen, W Huang, M J Harding, S C Hamon, T R Kosten

Open access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 2 pooled it
1.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 2 syntheses or guidelines pooled it, 30 citations in OpenAlex.

  1. Disulfiram for the treatment of cocaine dependence.The Cochrane database of systematic reviews · 2024
    Pooled it
  2. Pooled it
  3. Trial
  4. Functional neural changes following behavioral therapies and disulfiram for cocaine dependence.Psychology of addictive behaviors : journal of the Society of Psychologists in Addictive Behaviors · 2017
    Trial
  5. Trial
  6. Review
  7. Article
  8. Pharmacogenetics of Addiction Therapy.Methods in molecular biology (Clifton, N.J.) · 2022
    Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

D ShorterMichael E. DeBakey V.A. Medical Center (MEDVAMC), Houston, TX, USA; Menninger Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, TX, USA. Electronic address: shorter@bcm.edu.
D A Nielsen
W Huang
M J Harding
S C Hamon
T R Kosten
Baylor College of Medicine · USMichael E. DeBakey VA Medical Center · USRockefeller University · US

Funding

Tiagabine and Disulfiram for Cocaine DependenceP50DA018197 · NIDA · YALE UNIVERSITY · PI NEWTON, THOMAS FREDERICK · 2004 to 2013
$12.6M
Clinical Research Education for Drug Abuse ProfessionalsR25DA028976 · NIDA · BAYLOR COLLEGE OF MEDICINE · PI NEWTON, THOMAS FREDERICK · 2011 to 2015
$1.2M
NIDA NIH HHS 5P50DA018197-05NIDA NIH HHS P50 DA018197NIDA NIH HHS R25 DA028976
6 · The paper itself

Abstract

Disulfiram is a cocaine addiction pharmacotherapy that inhibits dopamine β-hydroxylase (DβH) and reduces norepinephrine production. We examined whether a functional variant of the ADRA1A gene (Cys to Arg at codon 347 in exon 2, Cys347Arg) may enhance treatment response through decreased stimulation of this α1A-adrenoceptor, since antagonists of this receptor show promise in reducing cocaine use. Sixty-nine cocaine and opioid co-dependent (DSM-IV) subjects were stabilized on methadone for two weeks and subsequently randomized into disulfiram (250 mg/day, N=32) and placebo groups (N=37) for 10 weeks. We genotyped the ADRA1A gene polymorphism (rs1048101) and evaluated its role for increasing cocaine free urines in those subjects treated with disulfiram using repeated measures analysis of variance, corrected for population structure. The 47 patients who carried at least one T allele of rs1048101 (TT or TC genotype) reduced their cocaine positive urines from 84% to 56% on disulfiram (p=0.0001), while the 22 patients with the major allele CC genotype showed no disulfiram effect. This study indicates that a patient's ADRA1A genotype could be used to identify a subset of individuals for which disulfiram and, perhaps, other α1-adrenoceptor blockers may be an effective pharmacotherapy for cocaine dependence.

Indexed as

AdultAlcohol DeterrentsAllelesCocaine-Related DisordersDisulfiramDopamine beta-HydroxylaseFemaleGenotypeHumansMaleMethadoneOpiate Substitution TreatmentOpioid-Related DisordersPolymorphism, GeneticReceptors, Adrenergic, alpha-1Alcohol DeterrentsDisulfiramDopamine beta-HydroxylaseMethadoneReceptors, Adrenergic, alpha-1Cocaine dependenceDisulfiramGenePolymorphismα(1A)-adrenoceptor

Identifiers

PMID23849431
PMCPMC3818518
OpenAlexW2092305706

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.